XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
A
A

AstraZeneca

News

Reuters - 1 day ago

US natural gas prices drop to 7-week low on rising output, high storage levels

UPDATE 1-US natural gas prices drop to 7-week low on rising output, high storage levels Adds latest prices July 5 (Reuters) - U.S. natural gas futures slipped over 4% to a seven-week low on Friday, as rising output and ample gas supply in storage outweighed support from forecasts for higher demand over the next two weeks. Front-month gas futures NGc1 for August delivery on the New York Mercantile Exchange fell 9.5 cents , to settle at $2.31 9 per million British thermal units (mmBtu).
A
Reuters - 1 day ago

US natural gas prices drop to 7-week low on rising output, high storage levels

US natural gas prices drop to 7-week low on rising output, high storage levels July 5 (Reuters) - U.S. natural gas futures slipped nearly 2% to a seven-week low on Friday, as rising output and ample gas supply in storage outweighed support from forecasts for higher demand over the next two weeks. Front-month gas futures NGc1 for May delivery on the New York Mercantile Exchange were down 4.6 cents, or 1.9%, to $2.37 per million British thermal units (mmBtu) at 10:57 a.m.
A
N
Reuters - 1 day ago

Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial

BUZZ-Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial Updates ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN
A
R
Reuters - 2 days ago

Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial

BUZZ-Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN has colo
A
R
Reuters - 2 days ago

AstraZeneca Says Tagrisso With Addition Of Chemotherapy Approved In EU

BRIEF-AstraZeneca Says Tagrisso With Addition Of Chemotherapy Approved In EU July 5 (Reuters) - AstraZeneca PLC AZN.L : TAGRISSO WITH THE ADDITION OF CHEMOTHERAPY APPROVED IN THE EU AS NEW 1ST-LINE TREATMENT FOR PATIENTS WITH EGFR-MUTATED ADVANCED LUNG CANCER SAFETY PROFILE OF TAGRISSO PLUS CHEMOTHERAPY CONSISTENT WITH ESTABLISHED PROFILES OF INDIV
A
Reuters - 3 days ago

US natgas prices ease to 7-week low on output rise, ample storage

UPDATE 2-US natgas prices ease to 7-week low on output rise, ample storage Adds latest prices By Scott DiSavino July 3 (Reuters) - U.S. natural gas futures eased about 1% to a seven-week low on Wednesday on a rise in output so far in July and the oversupply of gas still in storage. Gas stockpiles were now about 19% above normal for this time of year.
A
N
Reuters - 3 days ago

US natgas prices hold near 7-week low ahead of storage report

US natgas prices hold near 7-week low ahead of storage report By Scott DiSavino July 3 (Reuters) - U.S. natural gas futures held near a seven-week low on Wednesday as the market waits for direction from what should be a bullish federal report expected to show last week's storage build was smaller than usual for an eighth week in a row. That lack of price movement came despite a bullish heat wave expected to linger over much of the country through at least mid--July and a bearish rise in output s
A
N
Reuters - 3 days ago

Absci gains after Morgan Stanley starts with 'overweight' rating

BUZZ-Absci gains after Morgan Stanley starts with 'overweight' rating ** Shares of Absci Corp ABSI.O rises 7.7% to $3.2 in premarket trading ** Morgan Stanley initiates coverage on the AI biologics firm with "overweight" rating and $7 price target, implying a more than twofold upside to last close ** ABSI is using its artificial intelligence and ma
A
A
Reuters - 4 days ago

A closer look at U.S. drug pricing risks

LIVE MARKETS-A closer look at U.S. drug pricing risks STOXX 600 up 0.8% Paris, Milan bourses outperform Fed rate cut bets support mood Wall St futures broadly unchanged Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com A CLOSER LOOK AT U.S.
A
A
E
N
U
E
F
I
U
G
Reuters - 4 days ago

Aptamer Group Says Agreement With AstraZeneca To Explore Optimer Vehicles For siRNA

BRIEF-Aptamer Group Says Agreement With AstraZeneca To Explore Optimer Vehicles For siRNA July 3 (Reuters) - Aptamer Group PLC APTA.L : AGREEMENT TO EXPLORE OPTIMER VEHICLES FOR SIRNA SIGNS AGREEMENT WITH ASTRAZENECA ASTRAZENECA TO PROVIDE SIRNA FOR TRIAL Source text for Eikon: ID:nRSC8869Ua Further company coverage: APTA.L
A
Reuters - 4 days ago

US natgas prices slide 2% to 6-week low on rising output, lower LNG feedgas

UPDATE 1-US natgas prices slide 2% to 6-week low on rising output, lower LNG feedgas Adds latest prices By Scott DiSavino July 2 (Reuters) - U.S. natural gas futures slid about 2% to a six-week low on rising output on Tuesday , forecasts for less demand over the next two weeks than previously expected due to lower liquefied natural gas (LNG) feedgas and an ongoing oversupply of gas in storage.
A
N
Reuters - 4 days ago

US drugmakers fall as Biden urges price cuts on obesity drugs

BUZZ-US drugmakers fall as Biden urges price cuts on obesity drugs ** Shares of U.S. drugmakers down between 1% and 2% after President Joe Biden and Senator Bernie Sanders, in an opinion piece on USA Today, called out Eli Lilly LLY.N and Novo Nordisk NOVOb.CO to reduce high costs of their weight loss drugs ** They also pointed to high prices of all medicines across the United States compared to other nations ** U.S.
A
G
P
R
Reuters - 4 days ago

US natgas prices ease to 6-week low on rising output, lower LNG feedgas

US natgas prices ease to 6-week low on rising output, lower LNG feedgas By Scott DiSavino July 2 (Reuters) - U.S. natural gas futures eased about 1% to a six-week low on rising output, forecasts for less demand over the next two weeks than previously expected due to lower liquefied natural gas (LNG) feedgas and an ongoing oversupply of gas in storage.
A
N
Reuters - 5 days ago

Battles over CEO pay across the globe

FACTBOX-Battles over CEO pay across the globe Recasts paragraphs 1 & 2 to add Salesforce shareholders rejecting CEO compensation plan; adds Tesla shareholders' approval of CEO Elon Musk's pay package July 2 (Reuters) - A majority of Salesforce CRM.N shareholders voted against a compensation plan for CEO Marc Benioff and other top executives, according to a security filing on Monday.
A
B
H
I
S
T
U
V
R
T
U
E
Reuters - 5 days ago

Cartesian's immune disorder therapy meets main goal in mid-stage study

UPDATE 2-Cartesian's immune disorder therapy meets main goal in mid-stage study Adds details and background in paragraphs 3 to 8, adds share movement in paragraph 10 July 2 (Reuters) - Cartesian Therapeutics RNAC.O said on Tuesday that its experimental therapy helped reduce symptoms of a rare, immune-related disorder, meeting the main goal in a mid-stage study.
A
Reuters - 5 days ago

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S
Reuters - 5 days ago

US natgas prices fall 5% to six-week low on output rise, lower demand forecast

UPDATE 2-US natgas prices fall 5% to six-week low on output rise, lower demand forecast Adds latest prices By Scott DiSavino July 1 (Reuters) - U.S. natural gas futures fell about 5% to a six-week low on rising output in recent weeks, forecasts for less demand over the next two weeks than previously expected and an ongoing oversupply of gas in storage.
A
N
Reuters - 5 days ago

US natgas prices fall 3% to one-month low on output rise, lower demand forecast

US natgas prices fall 3% to one-month low on output rise, lower demand forecast By Scott DiSavino July 1 (Reuters) - U.S. natural gas futures fell about 3% to a one-month low on rising output in recent weeks, forecasts for less demand over the next two weeks than previously expected and an ongoing oversupply of gas in storage. Analysts forecast there was still about 19% more gas in storage than usual for this time of year even though output reductions earlier in 2024 kept weekly injections below
A
N
Reuters - 6 days ago

UK Stocks-Factors to watch on July 1

UPDATE 1-UK Stocks-Factors to watch on July 1 Updates futures, adds items July 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Monday, with futures FFIc1 up 0.34%. * ASTRAZENECA: AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.
A
C
A
Reuters - 6 days ago

AstraZeneca's COVID prevention drug application gets EU fast-track assessment

UPDATE 1-AstraZeneca's COVID prevention drug application gets EU fast-track assessment Adds details and background in paragraphs 3-6 July 1 (Reuters) - AstraZeneca AZN.L said on Monday that the European Union drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, sipavibart, for an accelerated assessment.
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.